-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Things Look Grim For Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) After Today's Downgrade
Things Look Grim For Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) After Today's Downgrade
Today is shaping up negative for Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. Revenue and earnings per share (EPS) forecasts were both revised downwards, with analysts seeing grey clouds on the horizon. Surprisingly the share price has been buoyant, rising 19% to HK$5.25 in the past 7 days. Whether the downgrade will have a negative impact on demand for shares is yet to be seen.
After the downgrade, the two analysts covering Jacobio Pharmaceuticals Group are now predicting revenues of CN¥175m in 2022. If met, this would reflect a solid 17% improvement in sales compared to the last 12 months. Losses are supposed to balloon 21% to CN¥0.46 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of CN¥200m and losses of CN¥0.41 per share in 2022. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase.
Check out our latest analysis for Jacobio Pharmaceuticals Group
SEHK:1167 Earnings and Revenue Growth August 26th 2022The consensus price target fell 9.4% to CN¥11.15, with the analysts clearly concerned about the company following the weaker revenue and earnings outlook. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Jacobio Pharmaceuticals Group, with the most bullish analyst valuing it at CN¥19.09 and the most bearish at CN¥6.46 per share. We would probably assign less value to the forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. As a result it might not be possible to derive much meaning from the consensus price target, which is after all just an average of this wide range of estimates.
Of course, another way to look at these forecasts is to place them into context against the industry itself. One thing stands out from these estimates, which is that Jacobio Pharmaceuticals Group is forecast to grow faster in the future than it has in the past, with revenues expected to display 17% annualised growth until the end of 2022. If achieved, this would be a much better result than the 72% annual decline over the past year. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 40% per year. Although Jacobio Pharmaceuticals Group's revenues are expected to improve, it seems that the analysts are still bearish on the business, forecasting it to grow slower than the broader industry.
The Bottom Line
The most important thing to note from this downgrade is that the consensus increased its forecast losses this year, suggesting all may not be well at Jacobio Pharmaceuticals Group. Unfortunately analysts also downgraded their revenue estimates, and industry data suggests that Jacobio Pharmaceuticals Group's revenues are expected to grow slower than the wider market. With a serious cut to this year's expectations and a falling price target, we wouldn't be surprised if investors were becoming wary of Jacobio Pharmaceuticals Group.
As you can see, the analysts clearly aren't bullish, and there might be good reason for that. We've identified some potential issues with Jacobio Pharmaceuticals Group's financials, such as recent substantial insider selling. For more information, you can click here to discover this and the 2 other concerns we've identified.
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
今天对我们来说是负面的雅可比奥制药集团有限公司(HKG:1167)股东,分析师大幅下调今年的预测。营收和每股收益(EPS)预期双双下调,分析师认为地平线上将出现乌云。令人意外的是,该公司股价一直很高,在过去7天里上涨了19%,达到5.25港元。评级下调是否会对股票需求产生负面影响还有待观察。
在评级下调后,负责雅可比奥制药集团的两位分析师现在预测,2022年收入将达到1.75亿加元。如果得到满足,这将反映出与过去12个月相比,销售额稳步增长了17%。预计亏损将激增21%,至每股0.46元。然而,在最新估计之前,分析师们一直预测2022年营收为2亿加元,每股亏损0.41元。因此,在最近的共识更新之后,人们的观点发生了相当大的变化,分析师们大幅下调了收入预期,同时预计每股亏损将会增加。
查看我们对Jacobio制药集团的最新分析
联交所:1167盈利及收入增长2022年8月26日目标股价下跌9.4%,至11.15加元,分析师显然对该公司感到担忧,此前该公司营收和盈利前景较弱。看看分析师估计的范围,评估异常值与平均值的差异也可能是有启发意义的。对Jacobio PharmPharmticals Group有一些不同的看法,最乐观的分析师对其估值为19.09加元,最悲观的分析师估值为每股6.46元。在这种情况下,我们可能会对预测给予较低的价值,因为如此大的估计范围可能意味着,这项业务的未来很难准确估值。因此,可能不可能从共识价格目标中获得太大意义,毕竟这只是这一广泛估计范围的平均值。
当然,看待这些预测的另一种方式是将它们放在与行业本身相反的背景下。从这些估计中有一件事引人注目,那就是Jacobio PharmPharmticals Group预计未来的增长速度将快于过去,预计到2022年底,收入将出现17%的年化增长。如果实现,这将比过去一年72%的年降幅要好得多。相比之下,我们的数据显示,类似行业的其他公司(有分析师覆盖)的收入预计将以每年40%的速度增长。尽管Jacobio PharmPharmticals Group的收入预计将有所改善,但分析师似乎仍看空该业务,预计其增长速度将慢于更广泛的行业。
底线
从这次降级中需要注意的最重要的一件事是,共识增加了今年的预测亏损,这表明雅各比奥制药集团可能并不是一切都好。不幸的是,分析师也下调了他们的营收预期,行业数据显示,雅可比奥制药集团的营收增长预计将慢于更广泛的市场。随着今年预期的大幅下调和目标价的下降,如果投资者对雅各比奥制药集团变得谨慎起来,我们也不会感到惊讶。
正如你所看到的,分析师们显然并不看好股市,这或许是有充分理由的。我们已经发现了雅各比奥制药集团的一些潜在财务问题,例如最近的大规模内幕销售。有关更多信息,您可以单击此处了解这一点以及我们确定的其他两个问题。
搜索有趣的公司的另一种方式可能是到达拐点是跟踪管理层是在买入还是在卖出,我们的免费内部人士正在收购的成长型公司名单。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧